POPPY: Cardiometabolic Health in First Time Pregnancy

Sponsor

Cambridge University Hospitals NHS Foundation Trust (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05856318

Collaborator

University of Cambridge (Other), University of Bristol (Other), University College, London (Other), King's College London (Other), Imperial College London (Other), St George's, University of London (Other), University of Glasgow (Other), Wellcome Trust (Other)

3,500

Enrollment

Locations

354

Anticipated Duration (Months)

583.3

Patients Per Site

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Women who experience placental complications (syndromes) during pregnancy, such as pre-eclampsia (high blood pressure and kidney problems), gestational hypertension (high blood pressure during pregnancy) and fetal growth restriction (baby being small) have twice the risk of developing heart disease and diabetes later in life, compared to women who have a healthy pregnancy.

This study aims to assess risk factors for heart disease and diabetes in women who are actively trying to conceive, before and during their pregnancy, and 9-12 months after delivery of their baby, to see whether placental syndromes make a difference to their heart health. This will allow us to understand, if, and how, placental syndromes increase the risk of heart disease and diabetes, and, therefore, how best to reduce this risk and potentially prevent placental syndromes in the future. The investigators will also recruit women who are NOT planning pregnancy, as a control group.

Condition or Disease	Intervention/Treatment	Phase
Cardiometabolic Health Pregnancy Related Diabetes Placental; Syndrome, Dysfunction Heart Diseases

Detailed Description

Pre-eclampsia (PE), gestational hypertension (GH) and fetal growth restriction (FGR) share a common aetiology in that they arise from complex interactions between defective placentation, trophoblast dysfunction and the maternal cardiovascular and other systems. These placental syndromes affect approximately one in five nulliparous women and are a leading cause of maternal and child morbidity. Although usually considered self-limiting, and cured by delivery, placental syndromes are associated with an increased risk of maternal hypertension, diabetes and cardiovascular disease (CVD) in later life. Indeed, as summarised by NICE, PE is associated with a 4-fold increased risk of hypertension, and 2-fold excess risk of ischaemic heart disease and stroke. Similarly, Danish National Registry data show that women with GH have a 6-fold risk of subsequent hypertension, a 3-fold risk of diabetes and a 2-fold risk of CVD; similar to that reported for PE.

Whilst these risks have most impact in later life, they are evident almost immediately - women who develop hypertension in pregnancy have a 12 to 25-fold risk of developing permanent hypertension in the year after giving birth, compared to women with a normotensive pregnancy. Approximately one third of women in their 40s who had a hypertensive pregnancy, develop hypertension over the subsequent decade, compared with only 11% who had a normotensive pregnancy. Precursors of CVD (i.e. pre-clinical phenotypes) are also apparent in the early post-partum period in women who experience a placental syndrome. Increased aortic stiffness, elevated carotid intima-media thickness (cIMT) and left ventricular dysfunction have all been reported in women with previous PE/GH and FGR.

Whether placental syndromes simply "unmask" women with pre-existing (pre-conception) poor cardiometabolic health, or cause later maternal diabetes and CVD, remains unknown. If the former is correct, then improving cardiometabolic health in young women prior to conception could be key to reducing the incidence of placental syndromes. Conversely, if placental syndromes lead to CVD and diabetes independently of established cardiometabolic risk factors (e.g. by causing end organ damage), a focus on CVD/diabetes prevention in this high-risk group of women is likely to reduce the burden of these diseases. To date, studies with pre-conception measures of cardiometabolic risk factors are few, modest in patient number and detail, and have yielded conflicting results.

The study will test definitively, the hypothesis that placental syndromes adversely affect cardiometabolic health post-partum, independently of women's pre-conception cardiometabolic health. To do this, an observational, prospective study of healthy, nulliparous women, recruited pre-pregnancy will be undertaken.

Recruitment of the study population will utilise local advertisements and networks, social media and charitable organisations involved in pregnancy research. The study focus is nulliparous women to maximize the occurrence of placental syndromes (risk is highest in first pregnancies), and to remove any confounding effect of previous pregnancies.

The study does not involve randomisation of participants; participant study arm will be determined by individuals and their intention to conceive during the determined study period, or not, in line with the inclusion/exclusion criteria.

A sufficient number of women will be recruited to the Pregnancy arm of the study to yield 1500 viable pregnancies (_{3000 women, based on our feasibility data). Of these, the
investigators anticipate that 135 women will experience a placental syndrome, taking into
account attrition. A Non-Pregnancy study arm, women voluntarily planning not to conceive
during their involvement in the study; n}500 will also be recruited, to act as a control arm.

Individual participant study duration will last between approximately 12 and 33 months dependent on study arm and timings around pregnancy and follow-up. For those in the Non-Pregnancy arm study duration will last approximately 18 months, ending after the second follow up visit. Study duration for those in the Pregnancy arm will vary, between 12 months and 33 months, dependent on time from recruitment to pregnancy occurrence and/or occurrence of placental syndrome; those (Pregnancy arm) participants who do not become pregnant will experience a shorter study duration (12 months) and only a proportion of those experiencing a healthy pregnancy will attend a final follow-up visit 18 months after delivery.

The output of this study will primarily aim to determine to what extent the association between placental syndromes and maternal cardio-metabolic health post-pregnancy is explained by pre-pregnancy subclinical cardiometabolic health. As secondary aims the study also aims to determine which aspects of pre-pregnancy cardiometabolic health impact on women's cardiovascular adaptation to pregnancy; whether haemodynamic maladaptation is an early pregnancy biomarker for the later clinical manifestations of placental dysfunction; and whether an uncomplicated pregnancy results in improved maternal cardiometabolic health post-partum. Finally, the investigators will determine whether pre-pregnancy cardiovascular risk factors affect the rate of early fetal loss (miscarriage), which will answer an important clinical question, as recurrent miscarriage is associated with increased cardiovascular risk.

Study Design

Study Type:

Observational

Anticipated Enrollment :

3500 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Preconception to pOst-partum Study of Cardiometabolic Health in Primigravid PregnancY

Anticipated Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2027

Anticipated Study Completion Date :

Dec 1, 2052

Arms and Interventions

Arm	Intervention/Treatment
Pregnancy ~3000 participants Actively planning to conceive within approximately 12 months of study registration. No previous pregnancies.
Non-Pregnancy ~500 participants Not planning to conceive within 18 months of study registration. No previous pregnancies.

Outcome Measures

Primary Outcome Measures

QRISK3 [Risk difference between women who experienced a healthy pregnancy and those who experienced a pregnancy complication at 9-12 months postpartum]
Predicted lifetime CVD risk

Secondary Outcome Measures

Blood Pressure Systolic, Blood Pressure Diastolic Pulse Wave Analysis: Supine Systolic BP, Supine diastolic BP, Central Systolic BP, Central diastolic BP, Supine MAP [Assessed at 9-12 months postpartum]
BP (mmHg)
Height [Assessed at 9-12 months postpartum]
m
BMI [Assessed at 9-12 months postpartum]
kg/m2
BMR [Assessed at 9-12 months postpartum]
KJ
Waist:Hip ratio [Assessed at 9-12 months postpartum]
Waist measurement (cm), Hip measurement (cm), Waist/Hip measurement
Body fat (%), Tanita (%) [Assessed at 9-12 months postpartum]
(Tanita scales)
Weight, Fat mass, Fat free mass, Total body water [Assessed at 9-12 months postpartum]
kg
Sodium, Potassium, Urea, Total Cholesterol, Triglyceride, HDL-Cholesterol, LDL-cholesterol, Non-HDL cholesterol [Assessed at 9-12 months postpartum]
Lipids (mmol/L)
Creatinine [Assessed at 9-12 months postpartum]
Lipids (µmol/L)
HbA1c [Assessed at 9-12 months postpartum]
Lipids (mmol/mol)
White blood count (WBC), Platelet count, Neutrophil count, Lymphocyte count, Monocyte count, Eosinophil count, Basophil count [Assessed at 9-12 months postpartum]
Lipids (10*9/L)
Red blood cell (RBC) [Assessed at 9-12 months postpartum]
Lipids (10*12/L)
Haemoglobin (Hb) Haemoglobin (Hb) Haemoglobin (Hb) [Assessed at 9-12 months postpartum]
Lipids (g/L)
Haematocrit [Assessed at 9-12 months postpartum]
Lipids (L/L)
Mean cell volume (MCV) [Assessed at 9-12 months postpartum]
Lipids (fL)
Mean cell haemoglobin (MCH) [Assessed at 9-12 months postpartum]
Lipids (pg)
Red cell distribution width (RDW) [Assessed at 9-12 months postpartum]
Lipids (%)
Urine [Assessed at 9-12 months postpartum]
Protein, Blood, Glucose, Leukocytes, Nitrites
APWV: Aortic Pulse Wave Velocity, Carotid Intima-media thickness [Assessed at 9-12 months postpartum]
Suprasternal notch to distal (Femoral artery) (mm), Suprasternal notch to proximal (carotid artery) (mm), Carotid IMT (mm)
Oral glucose tolerance test (OGGT) [Assessed at 24-28 weeks pregnancy]
mmol
Diabetes Risk [Risk difference between women who experienced a healthy pregnancy and those who experienced a pregnancy complication at 9-12 months postpartum]
QDiabetes 2018

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Pregnancy Arm Inclusion Criteria:

To be included in the trial the participant must:

Nulliparous (no previous pregnancy beyond 20 weeks' gestation)
Actively considering pregnancy within approximately 12 months
Aged between 18 and 45 years
Ability to consent and willing to participate

Pregnancy Arm Exclusion Criteria:

The presence of any of the following will preclude participant inclusion:

Currently pregnant
Established infertility
Planning or actively using fertility treatments (e.g. IVF, ICSI, FET, IUI)
Assigned male sex at birth
Autoimmune disease (e.g. rheumatoid arthritis, lupus)
Thrombophilia
Type 1 diabetes
Known advanced chronic kidney disease (stages 4-5)
Malignant hypertension
Clinically manifest CVD (e.g. previous myocardial infarction, stroke)
Active cancer/being treated for cancer currently (other than skin cancer)
Any other condition preventing full participation in the study

Non-Pregnancy Arm Inclusion criteria

To be included in the trial the participant must:

Nulliparous (no previous pregnancy beyond 20 weeks' gestation)
Not planning to conceive during next 18 months
Aged between 18 and 45 years
Ability to consent and willing to participate

Non-Pregnancy Exclusion Criteria

The presence of any of the following will preclude participant inclusion:

Currently pregnant
Planning or actively using fertility treatments (e.g. IVF, ICSI, FET, IUI)
Assigned male sex at birth
Autoimmune disease (e.g. rheumatoid arthritis, lupus)
Thrombophilia
Type 1 diabetes
Known advanced chronic kidney disease (stages 4-5)
Malignant hypertension
Clinically manifest CVD (e.g. previous myocardial infarction, stroke)
Active cancer/being treated for cancer currently (other than skin cancer)
Any other condition preventing full participation in the study

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Cambridge University Hospitals NHS Foundation Trust	Cambridge	United Kingdom	CB2 0QQ
2	NHS Greater Glasgow and Clyde	Glasgow	United Kingdom
3	University College London Hospitals NHS Foundation Trust	London	United Kingdom	NW1 2BU
4	King's College Hospital NHS Foundation Trust	London	United Kingdom	SE5 9RS
5	St George's University Hospitals NHS Foundation Trust	London	United Kingdom	SW17 0QT
6	Imperial College Healthcare NHS Trust	London	United Kingdom	W2 1NY

Investigators

Principal Investigator: Ian Wilkinson, MD, Cambridge University Hospitals NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Dr Ian B Wilkinson, Head of Division, Division of Experimental Medicine & Immunotherapeutics, Cambridge University Hospitals NHS Foundation Trust

ClinicalTrials.gov Identifier:

NCT05856318

Other Study ID Numbers:

POPPY

First Posted:

May 12, 2023

Last Update Posted:

May 12, 2023

Last Verified:

May 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Dr Ian B Wilkinson, Head of Division, Division of Experimental Medicine & Immunotherapeutics, Cambridge University Hospitals NHS Foundation Trust

Additional relevant MeSH terms:

Heart Diseases